摘要
目的探讨罗格列酮（Rosiglitazone）的抗炎、抗动脉粥样硬化（AS）作用及其机制。方法应用彩色多普勒超声测量颈动脉内中膜厚度（IMT）及斑块情况以判定颈动脉粥样硬化，将2型糖尿病颈动脉粥样硬化患者随机分为罗格列酮治疗组和非罗格列酮治疗组。采用酶联免疫吸附（ELISA）法测定血清基质金属蛋白酶-9（MMP-9）、C-反应蛋白（CRP）水平，观察罗格列酮治疗前后MMP-9、CRP水平变化及与非罗格列酮治疗组之间变化的差别。结果应用罗格列酮治疗组治疗2周时的血清MMP-9、CRP水平分别为[397．3（282．4—600．9）]μg/L、[3．54（1．68—8．48）]mg／L，较治疗前水平[600．3（467．1—836．2）]μg／L、[5．98（3．90—10．92）]mg／L明显下降，且较非罗格列酮治疗组下降更加明显，而空腹血糖（FPG）在两治疗组问无显著性差异。罗格列酮治疗12周时的血清MMP-9、CRP水平较治疗2周时明显下降，分别为[259．3（136．0—495．2）]μg/L，[1．71（1．01—4．63）]mg/L。结论罗格列酮具有抗炎及独立于降糖之外的抗AS作用，且在一定时期内具有时间依赖性。
Objective To investigate the anti-inflammation and anti-atherosclerosis effects of Rosiglitazone. Methods Intima-media thickness （IMT）, plaque and hemodynamics were measured using colored duppler supersonic in the type 2 diabetic patients. The type 2 diabetic patients were derided randomly into two groups with and without Rosiglitazone treatment. The serum matrix metalloproteinase-9 （MMP-9）, C-reactive protein were determined by ELISA. Observe the differences after treatment between the groups with Rosiglitazone treatment and without Rosiglitazone treatment. Results The serum MMP-9, CRP levels were [ 397.3 （282.4-600. 9） ] μg/L, [3.54（ 1.68-8.48 ） ] mg/L respectively after Rosiglitazone treatment for 2W which were decreaced than that of baseline which were [ 600.3 （467.1-836.2） ] μg/L, [5.98 （3.90-10.92） ] mg/L. And the changes were significant than the group without Rosiglitazone treatment. However the changes of FPG in the two groups has no difference. The serum MMP-9, CRP levels were[ 259.3（136.0-495.2） ] μg/L, [ 1.71 （1.01-4.63） ] mg/L respectively after Rosiglitazone treatment for 12W which were decreaced significantly than that for 2W. Conclusion Rosiglitazone has anti-inflarnmative and anti-atherosclerotic effects indepandent of the lowering blood glucose. And the lowering blood glucose and anti-atherosclrotic effects was depended on time in the oeriord.
出处
《临床内科杂志》
CAS
2006年第5期334-336,共3页
Journal of Clinical Internal Medicine
基金
河北省科技局项目(NO.052761583)
